Chemoprevention of colorectal cancer: two steps forward, one step back? (Q36677468)

15 August 2017

1 reference

title

Chemoprevention of colorectal cancer: two steps forward, one step back? (English)

1 reference

15 August 2017

1 reference

1 reference

Elizabeth E Half

1

1 reference

PubMed ID

17155896

15 August 2017

Nadir Arber

series ordinal

2

1 reference

PubMed ID

17155896

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

15 August 2017

1 reference

15 August 2017

2

1 reference

15 August 2017

697-704

1 reference

15 August 2017

6

1 reference

15 August 2017

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

A genetic model for colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Genetic testing for high-risk colon cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Do NSAIDs prevent colorectal cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

NSAIDs and chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Aspirin use and reduced risk of fatal colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Colon cancer: detection and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Celecoxib for the prevention of colorectal adenomatous polyps

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

The therapeutic potential of NO-NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Lack of small intestinal ulcerogenecity of nitric oxide-releasing indomethacin, NCX-530, in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Nitric-oxide-donating NSAIDs as agents for cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Chemopreventive effect of farnesol and lanosterol on colon carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Statins and the risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Ursodiol: good drug makes good

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Modifiable risk factors for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

21 January 2018

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

Aspirin and the Risk of Colorectal Cancer in Women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.697

21 January 2018

Identifiers

DOI

10.2217/14796694.2.6.697

1 reference

15 August 2017

1 reference

PubMed ID

17155896